
    
      This study will be a placebo-controlled, double-blind, cross-over drug tria. Patients with
      Primary Fibromyalgia or Gulf War Syndrome will be recruited from the Stanford University Pain
      Management Center and the surrounding community. Participation in the study will cover 22
      weeks. Participants will attend a laboratory session 12 times for progress checkups, and will
      complete daily measures of symptoms.
    
  